source
- Telehealth firms Hims & Hers and Noom launch prescription peptide programs after HHS rule changeTelehealth companies Hims & Hers and Noom announced this week that they will begin prescribing peptide products to eligible patients, marking the first major consumer‑focused rollouts of such thera…
- Novartis forecasts modest 5% growth, bets on pipeline as Kisqali loses patentNovartis told investors it expects slower top‑line growth, narrowing its sales guidance to about 5% annual increase through 2031 as the breast‑cancer drug Kisqali faces patent expiry and price pres…